Thera-SAbDab

DARATUMUMAB

> Structural Summary

Therapeutic	Daratumumab
Target	CD38
Heavy Chain	EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
Light Chain	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Active
Recorded Developmental Technology	Medarex HuMAb Mouse
INN Year Proposed	2009
INN Year Recommended	2010
Companies Involved	Boston Medical Center, Bristol-Myers Squibb, Dana-Farber Cancer Institute, French Innovative Leukemia Organisation, Genentech, Genmab, Janssen Biotech, Janssen Research & Development, M. D. Anderson Cancer Center, Syros Pharmaceuticals
Conditions Approved	Multiple myeloma
Conditions Active	Amyloid light-chain amyloidosis, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Myelodysplastic syndromes, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor T-cell lymphoblastic leukaemia-lymphoma, Prostate cancer, T-cell lymphoma, Waldenstrom's macroglobulinaemia, Solid tumours
Conditions Discontinued	Non-small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]